Expertise in
18
conditions

Dr. Grant R. Seeger

Radiation Oncology
Altru Health System
1200 S Columbia Rd, 
Grand Forks, ND 
Accepting New Patients
Offers Telehealth
Expertise in
18
conditions
Altru Health System
1200 S Columbia Rd, 
Grand Forks, ND 

Overview

Grant Seeger is a Radiation Oncologist practicing medicine in Grand Forks, North Dakota.

Dr. Seeger is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Familial Prostate Cancer, Small Cell Lung Cancer (SCLC), and Posterior Fossa Tumor.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 40 clinical trials. Dr. Seeger is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in MN

Hospital Affiliations

Pembina County Memorial Hospital
Lifecare Medical Center
Sanford Thief River Falls Medical Center
Altru Hospital
Dickinson County Memorial Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Sanford Health
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Altru Health System
1200 S Columbia Rd, Grand Forks, ND 58201
Other Locations
Altru Cancer Center
960 S Columbia Rd, Grand Forks, ND 58201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

40 Clinical Trials

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Trametinib
Study Phase: Phase 2
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Drug, Radiation
Study Drugs: Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Relugolix, Triptorelin
Study Phase: Phase 3
View 9 Less Clinical Trials

3 Total Publications

N-Acetylcysteine Rinse for Thick Secretion and Mucositis of Head and Neck Chemoradiotherapy (Alliance MC13C2): A Double-Blind Randomized Clinical Trial.
N-Acetylcysteine Rinse for Thick Secretion and Mucositis of Head and Neck Chemoradiotherapy (Alliance MC13C2): A Double-Blind Randomized Clinical Trial.
Journal: Mayo Clinic proceedings
Published: August 28, 2018
Similar Doctors
Expertise in
4
conditions
Dr. William R. Noyes
Radiation Oncology
Expertise in
4
conditions
Dr. William R. Noyes
Radiation Oncology
Referral may be required

William Noyes MD PC

1451 44th Ave S Ste E, 
Grand Forks, ND 
 (4.6 miles away)
701-787-5800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

William Noyes is a Radiation Oncologist practicing medicine in Grand Forks, North Dakota. Dr. Noyes is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Familial Prostate Cancer, Prostate Cancer, Melanoma, and Marginal Zone Lymphoma (MZL). Dr. Noyes is currently accepting new patients.

Expertise in
2
conditions
Dr. Marshall B. Winchester
Radiation Oncology
Expertise in
2
conditions
Dr. Marshall B. Winchester
Radiation Oncology
Referral may be required

Altru Cancer Center

960 S Columbia Rd, 
Grand Forks, ND 
 (0.2 miles away)
701-780-5400
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Marshall Winchester is a Radiation Oncologist practicing medicine in Grand Forks, North Dakota. Dr. Winchester is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Muscle Invasive Bladder Cancer, Lung Cancer, and Familial Prostate Cancer. Dr. Winchester is currently accepting new patients.

Expertise in
0
conditions
Nicole L. Hylden, NP
Radiation Oncology
Expertise in
0
conditions
Nicole L. Hylden, NP
Radiation Oncology
Referral may be required

Altru Cancer Center

960 S Columbia Rd, 
Grand Forks, ND 
 (0.2 miles away)
701-780-5400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nicole Hylden is a Radiation Oncologist practicing medicine in Grand Forks, North Dakota. Her clinical expertise encompasses Familial Prostate Cancer, Prostate Cancer, Intraductal Papilloma, and Breast Cancer. Dr. Hylden is currently accepting new patients.

Frequently Asked Questions about Dr. Grant R. Seeger

How do I make an appointment with Dr. Grant R. Seeger?

You can book an appointment with Dr. Grant R. Seeger by calling their office at 701-780-5400. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Grant R. Seeger a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Grant R. Seeger is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Grant R. Seeger specialize in?

While Dr. Grant R. Seeger is a Radiation Oncology, they have specific expertise in Lung Cancer, Familial Prostate Cancer, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Grant R. Seeger participate in research or clinical trials?

Yes. Dr. Grant R. Seeger has published 3 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Grant R. Seeger's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Grant R. Seeger accept my insurance?

Dr. Grant R. Seeger accepts most major insurance plans, including Blue Cross Blue Shield and Cigna. We recommend calling the office directly at 701-780-5400 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Seeger's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 47 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile